Depakene and Developmental coordination disorder - a phase IV clinical study of FDA data

Summary:

Developmental coordination disorder is reported as a side effect among people who take Depakene (valproic acid), especially for people who are male, 0-1 old, also take Carbamazepine, and have Drug exposure during pregnancy.

The phase IV clinical study analyzes which people have Developmental coordination disorder when taking Depakene. It is created by eHealthMe based on reports of 14,611 people who have side effects when taking Depakene from the FDA, and is updated regularly.

What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,776 Depakene users. Check the latest studies of Depakene.

What is Developmental coordination disorder?

Developmental coordination disorder is found to be associated with 18 drugs and 79 conditions by eHealthMe. Check the latest studies of Developmental coordination disorder.

On Jul, 13, 2026

14,611 people reported to have side effects when taking Depakene.
Among them, 36 people (0.25%) have Developmental coordination disorder.

Could Depakene cause Developmental coordination disorder?

Among these 36 people:

What is the gender of people who have Developmental coordination disorder when taking Depakene? *

female: 37.5 %
male: 62.5 %

What is the age of people who have Developmental coordination disorder when taking Depakene? *

What are other drugs people take besides Depakene? *

What are other side effects people have besides Developmental coordination disorder? *

Abnormal Behavior: 7 people, 19.44%
Dysmorphism (difference of body structure that is suggestive of a congenital disorder): 7 people, 19.44%
Developmental Delay: 7 people, 19.44%
Hearing Impaired: 6 people, 16.67%
Nearsightedness (difficulty in seeing the far objects): 6 people, 16.67%
Echolalia (meaningless repetition of another person's spoken words -psychiatric disorder): 6 people, 16.67%
Otitis (ear infection): 6 people, 16.67%
Hair Growth Abnormal: 6 people, 16.67%
Joint Hyperextension (a joint is overstretched or ""bent backwards): 6 people, 16.67%
Hand Deformity: 6 people, 16.67%

What are the existing conditions these people have? *

Drug Exposure During Pregnancy: 10 people, 27.78%
Neonatal Asphyxia (a condition in which an extreme decrease in the concentration of oxygen in the body accompanied by an increase in the concentration of carbon dioxide in neonate): 1 person, 2.78%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and have Developmental coordination disorder?

- Check whether Developmental coordination disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Depakene:

Depakene (14,776 reports)

Browse all side effects of Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Developmental coordination disorder:

Developmental coordination disorder (18 drugs)

Browse all the conditions that are associated with Developmental coordination disorder:

Developmental coordination disorder (79 conditions)

Related publications that referenced our studies

Gupta E, Kunjal R, Cury JD, "Severe hyponatremia due to valproic acid toxicity", Journal of clinical medicine research, 2015 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .
Gupta E, Kunjal R, Cury JD, "Severe hyponatremia due to valproic acid toxicity", Journal of clinical medicine research, 2015 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid (the active ingredients of Depakene) and Depakene (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.